Filtered By:
Specialty: Hematology
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 1625 results found since Jan 2013.
Immunity in Stroke: The Next Frontier
Thromb Haemost. 2022 Jun 10. doi: 10.1055/s-0042-1748890. Online ahead of print.ABSTRACTTranslational stroke research has long been focusing on neuroprotective strategies to prevent secondary tissue injury and promote recovery after acute ischemic brain injury. The inflammatory response to stroke has more recently emerged as a key pathophysiological pathway contributing to stroke outcome. It is now accepted that the inflammatory response is functionally involved in all phases of the ischemic stroke pathophysiology. The immune response is therefore considered a breakthrough target for ischemic stroke treatment. On one side,...
Source: Thrombosis and Haemostasis - June 10, 2022 Category: Hematology Authors: Ting Li Arthur Liesz Source Type: research
Point of Care Assessment of Direct Oral Anticoagulation in Acute Ischemic Stroke: Protocol for a Prospective Observational Diagnostic Accuracy Study
This study will test the hypothesis that hyperacute point-of-care assessment of clotting time in the patient's whole blood has sufficient diagnostic accuracy to determine immediately whether stroke patients are pretreated with DOAC. Methods/ Design: This will be a prospective single-center diagnostic accuracy study in 1850 consecutive acute ischemic stroke patients at a tertiary stroke center in Saxony, Germany. Presence of active anticoagulation with DOAC will be determined by point-of-care quantification of clotting time via whole blood viscoelastic testing (ClotPro®) using Russell venom viper and Ecarin assay compared ...
Source: Thrombosis and Haemostasis - June 7, 2022 Category: Hematology Authors: Annahita Sedghi Lars Heubner Anna Klimova Oliver Tiebel J örg Pietsch Martin Mirus Kristian Barlinn Tabea Tabita Talita Tatjana Minx Jan Beyer-Westendorf Volker Puetz Peter Spieth Timo Siepmann Source Type: research
Ischemic Stroke with Cancer: Hematologic and Embolic Biomarkers and Clinical Outcomes
CONCLUSIONS: Markers of hypercoagulability and embolic disease may be associated with adverse clinical outcomes in cancer-related stroke.PMID:35652416 | DOI:10.1111/jth.15779
Source: Thrombosis and Haemostasis - June 2, 2022 Category: Hematology Authors: Babak B Navi Cenai Zhang Carla P Sherman Richard Genova Natalie M LeMoss Hooman Kamel Scott T Tagawa Ashish Saxena Allyson J Ocean Scott E Kasner Mary Cushman Mitchell S V Elkind Ellinor Peerschke Lisa M DeAngelis Source Type: research
Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data
For stroke prevention in patients with atrial fibrillation (AF), direct oral anticoagulants (DOACs) have been increasingly prescribed instead of vitamin-K-antagonists (VKA). For some patients a lower dosage of...
Source: Thrombosis Journal - May 26, 2022 Category: Hematology Authors: Lisette Warkentin, Susann Hueber, Barthold Deiters, Florian Klohn and Thomas K ühlein Tags: Research Source Type: research
Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY
Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for stroke prevention in atrial fibrillation (SPAF). Outcome data on clinical effectiveness and safety in routine care are increasing.
Source: Thrombosis Research - May 22, 2022 Category: Hematology Authors: Christina K öhler, Luise Tittl, Sandra Marten, Christiane Naue, Marianne Spindler, Laura Stannek, Kristina Fache, Jan Beyer-Westendorf Tags: Letter to the Editors-in-Chief Source Type: research
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases
ConclusionsIn this real-world analysis of a large sample of NVAF patients with prior bleeding, NOACs were associated with similar or lower risk of stroke/SE and MB vs. warfarin and variable risk of stroke/SE and MB against each other.
Source: Journal of Thrombosis and Thrombolysis - May 17, 2022 Category: Hematology Source Type: research
Clopidogrel monotherapy versus Aspirin monotherapy in patients with established cardiovascular disease: systematic review and meta-analysis
CONCLUSIONS: In patients with established cardiovascular disease, Clopidogrel was associated with a 17% relative-risk reduction for non-fatal MI, borderline decreased risk for MACE and similar risk for all-cause mortality, stroke and major bleeding compared to Aspirin.PMID:35577054 | DOI:10.1055/a-1853-2952
Source: Thrombosis and Haemostasis - May 16, 2022 Category: Hematology Authors: Panagiotis Tasoudis Ioannis Kyriakoulis Dimitrios Sagris Hans-Christoph Diener George Ntaios Source Type: research
Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels
Direct oral anticoagulants (DOACs) do not require routine coagulation monitoring but measuring plasma drug levels may be helpful in specific circumstances. For example, patients with DOAC drug levels below 30 to 50 ng/mL are unlikely to benefit from anticoagulant reversal strategies before an urgent medical procedure or to treat major bleeding [1] or may be suitable candidates for systemic thrombolysis in the setting of acute ischemic stroke [2].
Source: Thrombosis Research - May 12, 2022 Category: Hematology Authors: Siraj Mithoowani, Karen A. Moffat, Akash Gupta, Stephen A. Carlino, Mark A. Crowther Tags: Letter to the Editors-in-Chief Source Type: research
The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis
ConclusionsThe use of colchicine reduces the risk of stroke in patients with a history of coronary artery disease, without a significant increase in gastrointestinal and myopathy/myalgia adverse effects.
Source: Journal of Thrombosis and Thrombolysis - May 10, 2022 Category: Hematology Source Type: research
Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
The benefit of apixaban to reduce stroke risk in morbidly obese patients with nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of Thrombosis and Hemostasis recommends avoid...
Source: Thrombosis Journal - May 2, 2022 Category: Hematology Authors: Khalid Al Sulaiman, Hisham A. Badreldin, Ghazwa B. Korayem, Abeer A. Alenazi, Faisal Alsuwayyid, Abdulrahman Alrashidi, Mohammed Alhijris, Faisal Almutairi, Fahad Alharthi, Ramesh Vishwakarma, Omar Al Shaya, Abdulrahman Al Amri, Saqiba Tayyab, Abdulkareem Tags: Research Source Type: research
PO-11: Risk of major bleeding in cancer patients with ischemic stroke treated with thrombolysis
Source: Thrombosis Research - May 1, 2022 Category: Hematology Authors: N. Skajaa, K. Adelborg, F.S. Troelsen, C.H. Fuglsang, E. Horv áth-Puhó, H.T. Sørensen Tags: Posters Source Type: research
OC-12: Stroke and risk of cancer: a Danish population-based cohort study
Source: Thrombosis Research - May 1, 2022 Category: Hematology Authors: N. Skajaa, K. Veres, F.S. Troelsen, J.D. Petersen, K. Adelborg, H.T. S ørensen Tags: Oral Communications Source Type: research
